Monocyte and neutrophil adhesion to matrix proteins is selectively enhanced in the presence of inflammatory mediators.
The authors investigated the time course of monocyte and neutrophil adhesion to fibronectin, vitronectin and albumin precoated culture wells, using mixed leucocyte populations from healthy blood donors. Moreover, the influence of chemotactic agonists on the adhesion properties as well as the quantitative expression of CD29, CD11b/CD18 and CD61 was analysed by flow cytometry. Different chemotactic agonists were used representing a classical chemotactic agonist (fMLP), and agonists with a preferential effect on monocytes (RANTES) and neutrophils (IL-8), respectively. The authors found a gradual increase in monocyte and neutrophil adhesion to all three surfaces, reaching a plateau at 15 min of incubation. Adhesion to fibronectin was significantly higher at all time points (5, 15 and 60 min, respectively) compared with vitronectin and albumin in both monocytes and neutrophils. Neutrophil adhesion to vitronectin was significantly lower at 60 min compared with 15 min. Monocyte adhesion to albumin was increased by fMLP and RANTES and to vitronectin also by IL-8. Neutrophil adhesion to albumin and vitronectin was increased by fMLP and IL-8, but not RANTES. The adhesion to fibronectin was not altered by any of the chemotactic agonists used. The quantitative levels of CD11b/CD18, but not CD29 and CD61, was increased by fMLP, but not RANTES nor IL-8. The authors conclude that the adhesion of human monocytes and neutrophils to vitronectin and albumin, but not fibronectin, is selectively enhanced by chemotactic agonists and may contribute to the selective accumulation of different leucocyte subsets at the inflammatory site.
Lundahl
J
J
Department of Clinical Immunology and Transfusion Medicine, Karolinska Hospital, Stockholm, Sweden.
Sköld
C M
CM
Halldén
G
G
Hallgren
M
M
Eklund
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D018845:CD11 Antigens / Q000032:analysis; D018821:CD18 Antigens / Q000032:analysis; D002448:Cell Adhesion / Q000187:drug effects; D018946:Chemokine CCL5 / Q000494:pharmacology; D005353:Fibronectins / Q000502:physiology*; D006801:Humans; D018836:Inflammation Mediators / Q000494:pharmacology*; D016209:Interleukin-8 / Q000494:pharmacology; D008875:Middle Aged; D009000:Monocytes / Q000502:physiology*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000502:physiology*; D019096:Vitronectin / Q000502:physiology*
D018845:CD11 Antigens; D018821:CD18 Antigens; D018946:Chemokine CCL5; D005353:Fibronectins; D018836:Inflammation Mediators; D016209:Interleukin-8; D019096:Vitronectin; D009240:N-Formylmethionine Leucyl-Phenylalanine